Cargando…
Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden
INTRODUCTION: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) can reveal the metabolic activity of malignant tumors. Recent advances gained from molecular studies suggest that tumor biology can be a good predictor of prognosis in breast cancer. We compared the ability of maximum stan...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308858/ https://www.ncbi.nlm.nih.gov/pubmed/25551703 http://dx.doi.org/10.1186/s13058-014-0502-y |
_version_ | 1782354598527238144 |
---|---|
author | Ahn, Sung Gwe Park, Jong Tae Lee, Hak Min Lee, Hak Woo Jeon, Tae Joo Han, Kyunghwa Lee, Seung Ah Dong, Seung Myung Ryu, Young Hoon Son, Eun Ju Jeong, Joon |
author_facet | Ahn, Sung Gwe Park, Jong Tae Lee, Hak Min Lee, Hak Woo Jeon, Tae Joo Han, Kyunghwa Lee, Seung Ah Dong, Seung Myung Ryu, Young Hoon Son, Eun Ju Jeong, Joon |
author_sort | Ahn, Sung Gwe |
collection | PubMed |
description | INTRODUCTION: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) can reveal the metabolic activity of malignant tumors. Recent advances gained from molecular studies suggest that tumor biology can be a good predictor of prognosis in breast cancer. We compared the ability of maximum standardized uptake values (SUV(max)) derived by FDG-PET with tumor burden in predicting tumor recurrence for patients with breast cancer. METHODS: 496 patients with breast cancer who underwent preoperative FDG-PET between April 2004 and May 2009 were retrospectively identified. SUV(max) was obtained by FDG-PET, and the cutoff point was defined using a time-dependent receiver operating characteristic curve for recurrence-free survival (RFS). The primary endpoint was RFS. RESULTS: In multivariate analysis for RFS, SUV(max) carried independent prognostic significance (hazard ratio, 2.39; 95% confidence interval, 1.20 to 4.76; P = 0.012). When the patients were classified into four groups according to the combined factors of tumor size (≤2 cm versus >2 cm) and SUV(max) (<4 versus ≥4), RFS differed significantly (P < 0.001). Similarly, SUV(max) had prognostic value in combination with nodal status (negative versus positive) or stage (I versus II and III) (P < 0.001 and P = 0.001, respectively). In hormone receptor–positive disease, SUV(max) remained a significant prognostic factor for RFS based on multivariate analysis. CONCLUSIONS: Our results highlight the prognostic value of FDG-PET in prediction of tumor relapse for patients with breast cancer. Particularly in patients with hormone receptor–positive disease, the tumor metabolic information provided by FDG-PET is more significantly correlated with prognosis than tumor burden. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-014-0502-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4308858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43088582015-01-29 Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden Ahn, Sung Gwe Park, Jong Tae Lee, Hak Min Lee, Hak Woo Jeon, Tae Joo Han, Kyunghwa Lee, Seung Ah Dong, Seung Myung Ryu, Young Hoon Son, Eun Ju Jeong, Joon Breast Cancer Res Research Article INTRODUCTION: (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) can reveal the metabolic activity of malignant tumors. Recent advances gained from molecular studies suggest that tumor biology can be a good predictor of prognosis in breast cancer. We compared the ability of maximum standardized uptake values (SUV(max)) derived by FDG-PET with tumor burden in predicting tumor recurrence for patients with breast cancer. METHODS: 496 patients with breast cancer who underwent preoperative FDG-PET between April 2004 and May 2009 were retrospectively identified. SUV(max) was obtained by FDG-PET, and the cutoff point was defined using a time-dependent receiver operating characteristic curve for recurrence-free survival (RFS). The primary endpoint was RFS. RESULTS: In multivariate analysis for RFS, SUV(max) carried independent prognostic significance (hazard ratio, 2.39; 95% confidence interval, 1.20 to 4.76; P = 0.012). When the patients were classified into four groups according to the combined factors of tumor size (≤2 cm versus >2 cm) and SUV(max) (<4 versus ≥4), RFS differed significantly (P < 0.001). Similarly, SUV(max) had prognostic value in combination with nodal status (negative versus positive) or stage (I versus II and III) (P < 0.001 and P = 0.001, respectively). In hormone receptor–positive disease, SUV(max) remained a significant prognostic factor for RFS based on multivariate analysis. CONCLUSIONS: Our results highlight the prognostic value of FDG-PET in prediction of tumor relapse for patients with breast cancer. Particularly in patients with hormone receptor–positive disease, the tumor metabolic information provided by FDG-PET is more significantly correlated with prognosis than tumor burden. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13058-014-0502-y) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-31 2014 /pmc/articles/PMC4308858/ /pubmed/25551703 http://dx.doi.org/10.1186/s13058-014-0502-y Text en © Ahn et al.; licensee BioMed Central. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Ahn, Sung Gwe Park, Jong Tae Lee, Hak Min Lee, Hak Woo Jeon, Tae Joo Han, Kyunghwa Lee, Seung Ah Dong, Seung Myung Ryu, Young Hoon Son, Eun Ju Jeong, Joon Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden |
title | Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden |
title_full | Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden |
title_fullStr | Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden |
title_full_unstemmed | Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden |
title_short | Standardized uptake value of (18)F-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden |
title_sort | standardized uptake value of (18)f-fluorodeoxyglucose positron emission tomography for prediction of tumor recurrence in breast cancer beyond tumor burden |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308858/ https://www.ncbi.nlm.nih.gov/pubmed/25551703 http://dx.doi.org/10.1186/s13058-014-0502-y |
work_keys_str_mv | AT ahnsunggwe standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden AT parkjongtae standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden AT leehakmin standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden AT leehakwoo standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden AT jeontaejoo standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden AT hankyunghwa standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden AT leeseungah standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden AT dongseungmyung standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden AT ryuyounghoon standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden AT soneunju standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden AT jeongjoon standardizeduptakevalueof18ffluorodeoxyglucosepositronemissiontomographyforpredictionoftumorrecurrenceinbreastcancerbeyondtumorburden |